Patent ID: 8163284

Claim:
A method of treating a TSLP-related inflammatory condition in a subject in need of such treatment comprising administering a therapeutically effective amount of a composition comprising an isolated TSLP antagonist antigen binding protein that specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2, wherein said TSLP antagonist antigen binding protein comprises: a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:13; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:60; and iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:105; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:145; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:173, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:212.